Use of Nose Drops Reduces Length of Young Children’s Colds
By Lori Solomon HealthDay Reporter
WEDNESDAY, Sept. 11, 2024 -- Hypertonic saline (HS) nose drops reduce the duration of symptoms associated with viral upper respiratory tract infections (URTI) in children, according to a study presented at the European Respiratory Society Congress, held from Sept. 7 to 11 in Vienna.
Steve Cunningham, from University of Edinburgh in Scotland, and colleagues investigated whether HS nose drops (2.6 percent) could reduce duration of illness among 407 children (ages 0 to 6 years) with a URTI. Children were randomly assigned (1:1) to parent-delivered HS nose drops (three drops per nostril, four or more times per day until well) or usual care (UC).
The researchers found that in the HS group, children received a median of five days of HS drops a median three times per day. Symptoms were a median duration of two days shorter with HS (six versus eight days with UC; P = 0.004). Shortened duration of symptoms was only seen when virus was detected, but not when virus was not detected via a nasal swab (P = 0.9). The most common virus detected was rhinovirus. In the HS group, fewer household contacts developed a URTI (41 versus 58 percent with UC; P = 0.008). No serious adverse events occurred.
“Salt is made up of sodium and chloride,” Cunningham said in a statement. “Chloride is used by the cells lining the nose and windpipes to produce hypochlorous acid within cells, which they use to defend against virus infection. By giving extra chloride to the lining cells, this helps the cells produce more hypochlorous acid, which helps suppress viral replication, reducing the length of the virus infection, and therefore the duration of symptoms.”
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Reporting of Human Adenoviruses Has Declined Since COVID-19
FRIDAY, Dec. 27, 2024 -- Reporting of human adenovirus (HAdV) types decreased since the COVID-19 pandemic, according to research published in the Dec. 19 issue of the U.S. Centers...
Just Over Half of Children Hospitalized With Flu Receive Antivirals
FRIDAY, Dec. 20, 2024 -- Just over half of children hospitalized with influenza receive antivirals, according to a study published online Dec. 17 in Clinical Infectious...
Combo Treatment With Xalnesiran Shows Promise in Patients With Hep B
FRIDAY, Dec. 13, 2024 -- For patients with chronic hepatitis B virus (HBV) infection with virologic suppression with nucleoside or nucleotide analog (NA) therapy, xalnesiran plus...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.